Thad Stappenbeck, MD, PhD, comments on the promise of the Pfizer vaccine, and how Cleveland Clinic will be prepared to administer doses as its one of the 10 distribution sites in Ohio.

Thad Stappenbeck, PhD, discusses how many people are likely to receive initial COVID-19 vaccine doses from companies Pfizer and Moderna (following FDA approval), and how “simply stunning” the early data is.

Feixiong Cheng, PhD, explains the details of his network medicine study that identified melatonin as a drug that may be repurposed to treat COVID-19, while cautioning that people should not change their medication routine based on this study alone.

Thad Stappenbeck, MD, PhD, shares what brings him optimism about the early results of the Pfizer vaccine trial, as well as what information is important to still learn, including length of immunity and its protection against severe infections.

Raed Dweik, MD, comments on a future Cleveland Clinic clinical trial planned for 2021 that will investigate how a portable breath test may be adapted to detect COVID-19, and the potential benefit of such a test over other rapid tests including ones that use saliva.

Timothy Chan, MD, PhD, comments on if it’s likely a COVID-19 vaccine will work for everyone, and what populations may be good candidates for treatment with a combination of vaccines.

Serpil Erzurum, MD, who’s working with the Operation Warp Speed federal initiative to find a vaccine, comments on possible vaccine timing and the number of candidate vaccines currently being tested.

Lara Jehi, MD, explains the value of a new Cleveland Clinic-developed risk calculator to predict COVID-19 severity and how biobanking efforts helped to support its development.

Serpil Erzurum, MD, and Jae Jung, PhD, discuss the new center and how its focus on viruses, immunology, personal medicine, genetics and population research will help protect us from SARS-CoV-2 and other emerging pathogens.

Physician-researcher Raed Dweik, MD, discusses the potential for breathalyzers in helping to detect COVID-19, as well as some of the general complexities and challenges that must be considered related to breath tests.

Raed Dweik, MD, explains some of the differences and benefits of preventing COVID-19 infections with vaccines versus treating already ill patients with drugs.

Mina Chung, MD, comments on the growing number of studies that suggest COVID-19 survivors experience related cardiovascular damage, including myocarditis.

Physician-researcher Stanley Hazen, MD, PhD, discusses his COVID-19 research and the evidence that suggests there may be a link between SARS-CoV-2 and the gut microbiome.

The nomogram developed by Lara Jehi, MD, and Michael Kattan, PhD, to predict a patient’s likelihood of testing positive for COVID-19 is mentioned as a tool that may provide clinicians a clearer sense of individual disease risk for their patients.

Serpil Erzurum, MD, comments on the effect the pandemic has had on the status of research studies and trials, and explains how LRI was able to adapt to avoid complete shutdown, unlike some other universities and research institutions.

Vijay Krishna, PhD, comments on the feasibility of engineering and treating patients with nanoparticles, called nanosponges, which attract and essentially inactivate SARS-CoV-2, the virus that causes COVID-19.

Raed Dweik, MD, comments on the accuracy of COVID-19 antibody tests, helping to clarify the difference in reliability of COVID-19 antibody and viral tests.

Feixiong Cheng, PhD, comments on new images showing how coronavirus creates tentacles that branch out and may transmit infection to neighboring cells.

Officials are talking about implementing a new strategy that tests groups of people together. Brian Rubin, MD, PhD, comments.

Lara Jehi, MD, explains how Cleveland Clinic is using the model—the first to predict a patient’s likelihood of testing positive for COVID-19—including to inform researchers and clinicians which patients should be followed more closely or hospitalized, and how resources should be allocated.

Lara Jehi, MD, explains how to interpret findings from the team’s recent study of a new predictive model, including that taking some medications is associated with lower risk for a positive COVID-19 test. She cautions that, at this point, the data does not suggest the medications are protective.

Christine McDonald, PhD, and Shaun Stauffer, PhD, share details about their work on COVID-19, including exploring how the disease occurs, what drives some of the complications and how they hope to target some of the body’s natural defenses.

Researchers Michael Kattan, PhD, and Lara Jehi, MD, discuss how their research builds on Cleveland Clinic’s model of clinical and scientific collaboration; how clinical data is facilitating unique investigations; and why waiting for government funding will hinder COVID-19 research.

Michael Kattan, PhD, joins Philanthropy Institute Chair Lara Kalafatis to discuss how predictive analytics are shaping care for patients with COVID-19, how his own battle with cancer inspired his life’s work and how Virtual VeloSano will support cancer research.

Tom Mihaljevic, MD, Cleveland Clinic CEO and President, and Serpil Erzurum, MD, Chair of Lerner Research Institute, discuss key COVID-19 research, including testing, vaccine development and anti-viral medications, as well as the importance of philanthropy in advancing COVID-19 treatments.

Early research about COVID-19 shows men have higher death rates and worse symptoms compared to women. Nima Sharifi, MD, is investigating whether that could be linked to sex hormones.

Antibody testing, which shows who has already been infected with COVID-19 and may have developed some levels of immunity, is not as straight forward as it sounds. Thaddeus Stappenbeck, MD, PhD, (beginning around minute 11) comments on the value of antibody testing during the COVID-19 pandemic.

Serpil Erzurum, MD, Chair of the Lerner Research Institute, and Philanthropy Institute Chair Lara Kalafatis discuss the race to develop a vaccine and promising research that is harnessing the power of big data to discover effective COVID-19 treatments.

Scientists are working to create a vaccine against SARS-CoV-2, but experts say it could take 12 to 18 months to develop and mass-produce. Thaddeus Stappenbeck, MD, PhD, provides insight on the complex process of vaccine development.